Drug Trial Radar · NCT07249788
Resmiterom Efficacy & Safety in Patients With MASH
Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Oct 17, 2025
Primary completion
Oct 16, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Nabiqasim Industries (Pvt) LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
ResmetiromDrug
1st FDA approved MASH therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- FIB-4 and CAP score/LSM on fibroscanTime frame: 6 months
- Changes in thyroid profileTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Liver transplant center, Holy family hospital
Rawalpindi, Punjab Province, Pakistan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.